Holen Sie sich die Stockscreener-App
18.47
3.82%
0.68
Handel nachbörslich:
18.36
-0.11
-0.60%
Schlusskurs vom Vortag:
$17.79
Offen:
$17.87
24-Stunden-Volumen:
2.48M
Relative Volume:
2.08
Marktkapitalisierung:
$1.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-183.79M
KGV:
-8.9266
EPS:
-2.0691
Netto-Cashflow:
$-131.84M
1W Leistung:
+4.71%
1M Leistung:
+4.82%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.82
$19.06
1-Wochen-Bereich:
$17.25
$19.67
52-Wochen-Spanne:
$14.62
$19.67
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
18.47 | 1.77B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum - Sahm
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.66 USD By Investing.com - Investing.com South Africa
Definium Therapeutics stock hits 52-week high at 19.66 USD - Investing.com
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - MarketBeat
Is It Too Late To Consider Definium Therapeutics (DFTX) After A 163% One Year Surge? - Sahm
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
DFTX: Definium Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
DFTX: Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs - TradingView
DFTX: Three pivotal data readouts for GAD and MDD expected in 2024, with strong Phase II results - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD - Investing.com Australia
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighHere's Why - MarketBeat
Definium Therapeutics Announces New Employee Inducement Grants - National Today
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (2026-03-09) - Seeking Alpha
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors - simplywall.st
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX - MarketBeat
Equities Analysts Set Expectations for DFTX Q1 Earnings - Defense World
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX) - The Globe and Mail
A Look At Definium Therapeutics (DFTX) Valuation As Wider Full Year Loss Refocuses Investor Expectations - simplywall.st
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - simplywall.st
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH) - The Globe and Mail
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):